Furthermore, a recent study has shown that major histocompatibility complex class I chain-related proteins A and B (MICA/B) drive NK cell antitumoral activity, providing preclinical evidence supporting MICA/B-specific 7C6 monoclonal antibody as a potential immunotherapeutic tool for iCCA [85]. This evidence concerns the gene MICA and infantile convulsions and choreoathetosis.